Sirolimus News and Research

RSS

Tacrolimus plus sirolimus not better than standard regimen in preventing GVHD

An experimental drug combination for preventing graft-versus-host disease (GVHD) was not significantly better than the standard regimen on key endpoints, according to a report of a phase 3 trial at the American Society of Hematology annual meeting.

11 Dec 2012

Novartis to highlight key data from extensive oncology portfolio at SABCS and ASH meeting

Novartis will highlight more than 140 presentations on key data from its extensive oncology portfolio at the leading year-end scientific meetings devoted to hematology and breast cancer, demonstrating continued innovation in research and development efforts to advance the care of patients with cancer and rare diseases.

30 Nov 2012

CHOP presents new findings on pediatric cardiovascular disease at AHA 2012

Physician-researchers from the Cardiac Center at The Children's Hospital of Philadelphia presented new findings on pediatric cardiovascular disease at the American Heart Association's Scientific Sessions 2012 in Los Angeles.

9 Nov 2012

Bone marrow transplants hold promise for sickle cell patients

Research shows that even partially matched bone marrow transplants are able to eliminate sickle cell disease in some patients with sickle cell anemia.

24 Sep 2012

Warning over sirolimus in HCV-positive liver transplantation

Sirolimus, whether given at the time of liver transplantation or after, is associated with poorer outcomes in patients with hepatitis C virus infection compared with those who do not take the immunosuppressant, shows a US study.

10 Sep 2012

PROTECT: Still no clear winner in the battle of the stent generations

Three-year rates of stent thrombosis with zotarolimus- and sirolimus-eluting stents are low and comparable, show results of the PROTECT trial.

29 Aug 2012

Diabetes journal reports results from novel experimental therapy

Results from a novel experimental therapy for Type 1 diabetes that boosts parts of the healthy immune system are reported today in the scientific journal Diabetes.

24 Aug 2012

Drug-eluting stents cleared for diabetes patients

All currently available drug-eluting stents are more effective than bare metal stents (BMS) for patients with diabetes, research suggests.

14 Aug 2012

Cardionovum to introduce PROLIMUS Biograde system in Europe

Cardionovum GmbH announced today that it expects to launch in Europe in Q4 2012 a next-generation Sirolimus-eluting coronary stent system—PROLIMUS Biograde—which is designed to optimize long-term patient results. Unlike many state-of-the-art DES that are currently being marketed, PROLIMUS Biograde provides multiple pro-healing product features to promote early re-endothelialization.

9 Aug 2012

Sirolimus has anti-skin cancer effect in kidney transplant patients

Switching from calcineurin inhibitors to a sirolimus-containing immunosuppression regimen may help reduce the incidence of secondary skin cancer after kidney transplantation, suggests research published in TheNew England Journal of Medicine.

27 Jul 2012

SIR/TAC combination more effective in preventing GVHD after allogeneic blood cell transplantation

Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug tacrolimus (TAC) in combination with either methotrexate (MTX ) or sirolimus (SIR), found that the sirolimus/tacrolimus (SIR/TAC) combination was more effective in preventing grades II-IV acute GVHD and moderate-severe chronic GVHD after allogeneic blood cell transplantation.

27 Jun 2012

STENTYS initiates enrollment in Self-Apposing Sirolimus-eluting stent trial for heart attack

STENTYS S.A., a medical technology company commercializing the world's first and only Self-Apposing Stent to treat Acute Myocardial Infarction (AMI), announced today that it has enrolled the first patient in its 'APPOSITION IV' clinical study using its new Self-Apposing Sirolimus-eluting stent.

From Medtronic 15 Jun 2012

Svelte completes enrollment in DIRECT drug-eluting stent study

Svelte Medical Systems today announced completion of enrollment in the DIRECT (Direct Implantation of Rapamycin-eluting stent with bio-Eroding Carrier Technology) study conducted at four investigational sites in New Zealand.

15 May 2012

Cardionovum to introduce two DEB dilatation catheter product families

Cardionovum GmbH will launch two drug-eluting balloon (DEB) dilatation catheter product families at next week's EuroPCR 2012 congress: Paclitaxel-coated drug-eluting balloons for coronary and peripheral applications.

11 May 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

Disrupting mTORC1 protein complex extends lifespan

One of the secrets to a longer, healthier life is simply to eat less. When subjected to calorie restriction (CR), typically defined as a 20-40% reduction in caloric intake with corresponding maintenance of proper nutrition, animals in labs not only live longer, but also have improved insulin sensitivity and glucose tolerance, both of which decline during aging.

30 Mar 2012

Center for LAM Research and Clinical Care at BWH to conduct phase I combination drug trial

The Center for LAM Research and Clinical Care at Brigham and Women's Hospital (BWH) has been awarded a $1 million plus, four-year grant from the U.S. Department of Defense Office of the Congressionally Directed Medical Research Programs to fund their work on lymphangioleiomyomatosis.

8 Feb 2012

Updated data from Novartis Afinitor plus everolimus Phase III study on advanced breast cancer

Updated results of a Phase III study of Afinitor (everolimus) tablets plus exemestane, a hormonal therapy, show everolimus provided additional time women with advanced breast cancer lived without their disease progressing.

8 Dec 2011

Novartis to showcase 160 presentations on breast cancer, hematological disease drugs at SABCS and ASH

Novartis Pharmaceuticals Corporation will showcase more than one hundred and sixty presentations on data from its robust oncology portfolio at two key medical congresses this month, demonstrating significant advances for patients with cancers and hematological diseases.

3 Dec 2011

Elixir Medical announces initiation of DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System study

Elixir Medical Corporation, a developer of products that combine state-of-the-art medical devices with advanced pharmaceuticals, announced enrollment initiation for a 120-patient, international pivotal clinical study to evaluate the safety and efficacy of the DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System designed to resorb in the body within 1 to 2 years after implantation and return the patients' coronary vessel to de novo state.

11 Nov 2011